Business · 24/09/2015
FDA Announces Public Comment Period for Study on Biosimilar Review Process
The FDA is seeking public input on the interim results of a study examining the workload volume and full costs associated with reviewing biosimilar biological product applications, as mandated by the Biosimilar User Fee Act of 2012.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →